Beyond Neurons: New Weight Loss Drug Targets Brain Support Cells, Promising Fewer Side Effects

For many individuals struggling with obesity and diabetes, the journey to sustainable weight loss is fraught with challenges. Existing pharmaceutical interventions, particularly GLP-1 receptor agonists like Ozempic and Zepbound, have demonstrated effectiveness in appetite suppression by targeting brain neurons. However, the prevalence of debilitating side effects, such as nausea and vomiting, often leads to treatment discontinuation, leaving patients in a cycle of weight loss and regain.

Now, a promising new avenue of research is emerging, shifting the focus from neurons to the often-overlooked "support cells" within the brain, offering a potential pathway to weight loss without the burdensome gastrointestinal distress.

The Limitations of Current GLP-1 Therapies

GLP-1 drugs function by mimicking the effects of a naturally occurring hormone, glucagon-like peptide-1 (GLP-1), which plays a crucial role in regulating appetite and blood sugar levels. These drugs target neurons in the brainstem, effectively reducing hunger and promoting weight loss.

However, the mechanism of action of GLP-1 drugs often triggers a cascade of physiological responses that can result in significant gastrointestinal side effects. The intensity of these side effects varies among individuals, but their frequent occurrence and severity contribute to a high rate of treatment abandonment. Specifically, it is estimated that 70% of patients discontinue GLP-1 treatment within the first year due to these adverse effects.

Unveiling the Potential of Brain Support Cells

Researchers, including Robert Doyle, a chemistry professor at Syracuse University, are exploring alternative therapeutic targets within the brain. Instead of solely focusing on neurons, they are investigating the role of "support cells," such as glia and astrocytes, in regulating appetite and metabolism. These support cells, traditionally viewed as playing a passive role in brain function, are now recognized as active contributors to neural signaling and metabolic control.

Imagine the brain as a complex electrical circuit. Neurons are the light bulbs, responsible for transmitting information. Support cells, on the other hand, are the wiring, switches, and power source, providing the necessary infrastructure for the light bulbs to function. Without these support cells, the neurons cannot effectively communicate or regulate bodily functions.

The Discovery of Octadecaneuropeptide (ODN)

Doyle and his team discovered that certain support cells in the hindbrain naturally produce a molecule called octadecaneuropeptide (ODN), which exhibits appetite-suppressing properties. In preclinical studies, direct injection of ODN into the brains of rats resulted in weight loss and improved glucose metabolism.

However, direct brain injection is not a feasible treatment option for humans. To overcome this obstacle, the researchers developed a modified version of the molecule called tridecaneuropeptide (TDN).

Tridecaneuropeptide (TDN): A Promising Alternative

TDN, unlike its predecessor ODN, can be administered through regular injections, similar to existing GLP-1 drugs. When tested in obese mice and musk shrews, TDN demonstrated significant weight loss and improved insulin sensitivity without causing nausea or vomiting.

The key to TDN's efficacy and reduced side effect profile lies in its ability to bypass neurons and directly target support cells. By taking this "shortcut," TDN avoids the cascade of chemical reactions triggered by GLP-1 drugs, thus minimizing the risk of gastrointestinal distress.

A New Approach to Weight Loss

The development of TDN represents a paradigm shift in the treatment of obesity and diabetes. By targeting support cells instead of neurons, this novel approach offers the potential for effective weight loss with minimal side effects.

As Doyle explains, "Instead of running a marathon from the very beginning like current drugs do, our targeting downstream pathways in support cells is like starting the race halfway through, reducing the unpleasant side effects many people experience… If we could hit that downstream process directly, then potentially we wouldn't have to use GLP-1 drugs with their side effects. Or we could reduce their dose, improving the toleration of these drugs. We could trigger weight loss signals that happen later in the pathway more directly."

CoronationBio: Bringing TDN to the Clinic

To translate this groundbreaking discovery into a real-world treatment, a new company called CoronationBio has been launched. CoronationBio has licensed intellectual property related to ODN derivatives from Syracuse University and the University of Pennsylvania. The company focuses on translating candidates into the clinic, with a goal of initiating human clinical trials as early as 2026 or 2027.

The future of weight loss and diabetes treatment may lie not in targeting neurons directly, but in harnessing the power of brain support cells. The development of TDN represents a significant step forward in this direction, offering hope for a new generation of therapies that are both effective and well-tolerated.

FAQs

1. How is TDN different from existing weight loss drugs like Ozempic?

TDN targets support cells in the brain, while Ozempic targets neurons. This difference in target allows TDN to bypass some of the chemical reactions that cause the unpleasant side effects associated with Ozempic, such as nausea and vomiting.

2. When will TDN be available to patients?

CoronationBio is planning to begin human clinical trials in 2026 or 2027. If the trials are successful, TDN could become available to patients in the following years.

3. What are the potential benefits of TDN compared to existing weight loss drugs?

The main potential benefit of TDN is that it may offer effective weight loss without the significant gastrointestinal side effects associated with GLP-1 drugs. This could lead to improved patient adherence and better long-term outcomes.

4. Are there any potential risks associated with TDN?

As with any new drug, there are potential risks associated with TDN. However, preclinical studies have shown that TDN is well-tolerated in animals. Human clinical trials will be necessary to fully assess the safety and efficacy of TDN.